Halle (Saale), Germany //
Probiodrug demonstrates first long-term effect of DP IV inhibition in the treatment of type 2 diabetes: normalisation of fasting blood glucose and improvement of insulin sensitivity. The respective patent was issued in the US (patent no. 6,500,804) on December 31, 2002. This is the second important step the company made to develop new concepts for the management of diabetes. In early 1996 it was also probiodrug, which introduced the use of DP IV-inhibitors for lowering elevated blood glucose levels in mammals as a completely new therapeutic concept, based on a broad medical use patent (US 6,303,661).